Vol. 55, No.
1, 2003
Free
Abstract Article
(References) Article
(PDF 107 KB)
Original Paper
Long-Term Administration of
Intravaginal Dehydroepiandrosterone on Regression of Low-Grade
Cervical Dysplasia - A Pilot Study Elizabeth
Suh-Burgmann, Julia Sivret, Linda R. Duska, Marcella Del
Carmen, Michael V. Seiden
Divisions of Gynecologic
Oncology and Hematology Oncology, Massachusetts General
Hospital, Boston,Mass.,USA
Address
of Corresponding Author
Gynecologic and Obstetric Investigation
2003;55:25-31 (DOI: 10.1159/000068953)
Key Words
- Chemoprevention
- Dehydroepiandrosterone
- Neoplasia
- Preinvasive cervical disease
- Cervix
- Dysplasia
Abstract
Although many dysplastic cervical lesions regress
spontaneously, treatment is common due to concern for
progression. Lesions persist or progress in women whose immune
systems are unable to clear infection by human papillomavirus
(HPV). Dehydroepiandrosterone (DHEA) is an adrenal steroid
that has both immune modulatory and tumor inhibitory activity.
A pilot study was conducted to examine the feasibility, safety
and potential efficacy of intravaginal DHEA in women with
low-grade cervical dysplasia. Twelve women with low-grade
dysplasia, confirmed by colposcopic exam, were given
150 mg of intravaginal micronized DHEA daily for up to
6 months. Follow-up evaluations of the cervix were done
at 3 and 6 months of use. DHEA, DHEA-S, androstenedione and
testosterone levels were also measured. By the end of the
study period, 10 of the 12 women (83%) had no evidence of
dysplasia; the remaining 2 had normal colposcopic exams but
cytology showing atypical cells of undetermined significance.
There were no serious side effects. Androstenedione levels
were elevated at 3 months, whereas testosterone levels were
unchanged over the course of treatment. The results suggest
that intravaginal DHEA is safe and well tolerated and may
promote regression of low-grade cervical lesions. Further
study is needed to establish efficacy.
Copyright © 2003 S. Karger AG, Basel
Author Contacts
Elizabeth Suh-Burgmann, MD Kaiser Permanente Medical
Center, Division of Gynecologic Oncology 2238 Geary, 5th
Floor San Francisco, CA 94115 (USA) Tel. +1 415 833
0389, Fax +1 415 833 4301, E-Mail Betty.Suh-Burgmann@kp.org
Article
Information
Received: June 10, 2002 Accepted after revision:
November 25, 2002 Number of Print Pages :
7 Number of Figures : 1, Number of Tables :
1, Number of References : 35 Free
Abstract Article
(References) Article
(PDF 107 KB)
|